What is HC Wainwright’s Estimate for LVTX Q2 Earnings?

LAVA Therapeutics (NASDAQ:LVTX) – Research analysts at HC Wainwright issued their Q2 2025 EPS estimates for shares of LAVA Therapeutics in a report released on Monday, March 31st. HC Wainwright analyst A. He expects that the company will post earnings of ($0.38) per share for the quarter. HC Wainwright has a “Neutral” rating and a $1.50 price objective on the stock. The consensus estimate for LAVA Therapeutics’ current full-year earnings is ($1.13) per share. HC Wainwright also issued estimates for LAVA Therapeutics’ Q3 2025 earnings at ($0.35) EPS and Q4 2025 earnings at ($0.33) EPS.

A number of other analysts also recently commented on the company. Leerink Partnrs downgraded LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Thursday, December 12th. Citizens Jmp lowered LAVA Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, December 11th. JMP Securities reissued a “market perform” rating and issued a $6.00 price target on shares of LAVA Therapeutics in a report on Wednesday, December 11th. Finally, Leerink Partners restated a “market perform” rating and set a $2.00 price target (down previously from $11.00) on shares of LAVA Therapeutics in a research report on Thursday, December 12th. Five research analysts have rated the stock with a hold rating, According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $3.17.

LAVA Therapeutics Stock Down 1.6 %

LAVA Therapeutics stock opened at $1.25 on Wednesday. LAVA Therapeutics has a 52 week low of $0.85 and a 52 week high of $3.57. The company’s 50 day moving average price is $1.14 and its two-hundred day moving average price is $1.36. The stock has a market cap of $32.87 million, a P/E ratio of -1.21 and a beta of 0.48.

LAVA Therapeutics (NASDAQ:LVTX) last released its quarterly earnings results on Friday, March 28th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.18. The firm had revenue of $2.50 million for the quarter, compared to analysts’ expectations of $2.40 million.

Institutional Trading of LAVA Therapeutics

A number of large investors have recently bought and sold shares of LVTX. Virtu Financial LLC purchased a new position in shares of LAVA Therapeutics during the 3rd quarter valued at $32,000. BNP Paribas Financial Markets bought a new stake in LAVA Therapeutics in the 4th quarter valued at about $40,000. Finally, Sanofi purchased a new stake in LAVA Therapeutics during the fourth quarter valued at about $1,825,000.

LAVA Therapeutics Company Profile

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.